Trial Profile

Phase II Trial of hOKT3gamma1(Ala-Ala) Teplizumab for Treatment of Patients With Recent Onset Type 1 Diabetes.

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 03 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Teplizumab (Primary)
Indications Type 1 diabetes mellitus
Focus Pharmacodynamics
Acronyms DELAY

Most Recent Events

06 Jul 2012 Status changed from active, no longer recruiting to completed, based on results presented at ADA.
12 Jun 2012 Final results presented at the 72nd Annual Scientific Sessions of the American Diabetes Association.
09 Jun 2012 Primary endpoint 'C-peptide-levels' has been met.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com